Interleukin-2 (IL-2) is able to induce the regression of metastatic cancers when administered in vivo. IL-2-activated natural killer cells and lymphocytes show, in vitro, activities against leukemic cells. To assess if in vitro observations could have significant clinical relevance, we evaluated the in vivo activity of high-dose recpmbinant IL-2 (6 to 8 x lo6 IU/m2/8" intravenous bolus for 5 days) in 10 patients with acute myeloid leukemias (AML) in relapse after chemotherapy (n = 7) or autologous bone marrow transplantation (n = 3). Two patients achieved a complete remission and one NTERLEUKIN-2 (IL-2) was initially described as a I factor produced by activated human T cells that was able to mediate the expansion of T cells in vitro.' Subsequently, the gene for IL-2 was cloned and expressed in Escherichia coli, '3' allowing the production of large amounts of a biologically active protein. Recombinant IL-2 (rIL-2), either alone in high dose or associated with lymphokineactivated killer cells (LAKs) or tumor-infiltrating lymphocytes (TILS), could induce regression of established cancer in mice and in some patients with metastatic disease^.^.'
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The importance of the immune system in the control of murine and human leukemic cells has been extensively shown in vitro.'@14 However, previous clinical trials of immunotherapy in acute myeloid leukemias (AML), using Bacillus-Calmette-Guerin (BCG) alone or associated with leukemic cells, failed to show a direct evidence of antileukemic a~tivity.'~,'~ More recently, the clinical evidence that a graft-versus-leukemia effect, mediated by T cells, was an essential mechanism in the curability of human leukemias by allogeneic bone marrow transplantation (BMT) could be established, stressing the potential clinical importance of immunotherapy in leukemia^."^'^ Thus, it has to be evaluated if modern forms of immunotherapy, using rIL-2, could affect the course of established leukemias. We report here the clinical results achieved by in vivo therapy with rIL-2 in 10 patients with AML in relapse or refractory disease, showing evidence of activity of high-dose IL-2 in this situation. 
PATIENTS AND METHODS

Patients
Ten eligible patients were included in this study (Table 1) . Criteria for inclusion were: (1) Cytologic diagnosis of primary AML, confirmed by cytochemistry and immunophenotypic analysis." (2) Standard induction chemotherapy by at least two courses of anthracyclines and aracytine followed by either maintenance chemotherapy or autologous BMT. (3) Established diagnosis of relapse or refractory leukemia by two marrow aspirates, at least a week apart, showing more than 10% blasts.21 (4) Absence of active infection, severe bleeding, or major illnesses of the cardiovascular, respiratory, or renal systems. (5) ECOG performance status 0 or 1.
The median age of patients was 49 years (range 5 to 68); and included seven males and three females. Marrow blasts before IL-2 ranged from 13% to 85% (median 68%). French-American-British (FAB) subclassification showed M1, two cases; M4, five cases; M5, three cases. Immunophenotype determination of leukemic cells was obtained either at diagnosis or at time of relapse (Table 1) . IL-2 was administered as a possible salvage therapy of a chemoresistant leukemia in five patients (including two primary resistant diseases); five other patients were treated by IL-2 as a first-line therapy for their relapse. For three patients, the relapse occurred 5 months (range 4 to 9) after an autologous BMT following cytoxan (120 mg/kg) and busulfan (16 mg/kg) (patients nos. 4,7, and 9).
Methods
rIL-2
rIL-2 (RU 49637) was kindly supplied by the Roussel-Uclaf Company (Romainville, France). The specific activity of this E coli rIL-2 was 10 x BRMP units per milligram of protein. The rIL-2 was reconstituted with sterile water and administered as 15-minute infusions in 50 mL of saline solution.
Treatment Schedule
IL-2 dose. Patient no. 1 received 6 x 10' U/m2/dose. After completion of a phase I study,22 all the other patients received 8 x 10' Uim'ldose.
ZL-2 schedule. Patients were scheduled to receive IL-2 in three cycles of 5 daysz2: the initial cycle was administered from day 1 through 5, the second from day 14 through 18, the third from day 28 through 32. IL-2 infusions were administered every 8 hours for the first cycle (15 doses) and every 12 hours for the second and third cycles (10 doses per cycle). During the cycles, IL-2 doses could be omitted depending on patient tolerance. All of the patients but one (no. 2) received at least two cycles of IL-2, and the third cycle was cancelled if patients showed evidence of disease progression (patient nos. 7 through 10). For personal use only. on September 14, 2017. by guest www.bloodjournal.org From 
Supportive Care
Patients were managed in a regular leukemia ward. All had a central venous line and received prophylactic antibiotics: Pefloxacine 400 mg every 12 hours (orally or intravenously [IV] ) and penicillin-G 1 million units every 12 hours (orally or IV). Packed red blood cells and pooled platelets were transfused to maintain hemoglobin greater than 8 g/dL and platelet counts greater than 20,000/mm3. Medications given to prevent some of the side effects of IL-2 administration included paracetamol (500 mg every 4 hours), indomethacin (50 mg every 8 hours), and ranitidine (150 mg every 12 hours) throughout the cycles of IL-2 therapy. If needed, meperidine (12.5 mg to 50 mg IV) was given for chills and chlorpromazine (5 to 12.5 mg IV) for nausea.
Vital signs were checked every 4 hours and fluid balance was evaluated every 8 hours. Furosemide (20 mg to 60 mg IV) was administered for fluid retention. Human albumin (4%) was rapidly infused for low blood pressure, and if correction was not adequate Dopamin was started (2.5 to 5 kg/kg/min).
Patients were clinically evaluated for tolerance every 8 hours and every 24 hours using usual biologic parameters. IL-2 infusions were discontinued if grade 3 World Health Organization toxicity occurred, except for hematologic parameters that were already abnormal in most patients at the onset of therapy.
All protocols were reviewed and accepted by the Ethical Committees of the participating institutions.
Phenotypic Analysis
Peripheral blood cells were analyzed during rIL-2 treatment on days 0,8 (after cycle l), and 36 (after cycle 3).
Both analyses of leukemic cells and peripheral blood cells were performed by two-color fluorescence analysis (ATC 3000; OdamBrucker, Wissembourg, France) using several antibodies: 80H5 (CD15) and 8H8 (CD7) were derived in the laboratory; IOT3 (CD3) was from Immunotech (Marseille, France). MY9 (CD33), MY4 (CD14), J5 (CDlO), and NKHl (CD56) were all from coulter (Hialeah, FL), and HPCA 1 (CD34) was from Becton Dickinson (San Jose, CA). Results were expressed as percent of positive cells and as mean of fluorescence intensity.
Natural killer (NK) activity was assayed using a chromium 51 (CR51) release assay using the NK-sensitive cell line K562 as target. LAK activity was similarly measured using the NK-resistant, LAK-sensitive Daudi cell line. Specific cytolysis values are expressed for an effector/target (E/T) cell ratio of 50/1.
Tumor Necrosis Factor-a (TNF-a) and Soluble IL-2 Receptor-a (IL-2Ra) Dosage
Samples were measured by enzyme-linked immunosorbent assay (ELISA) (Endogen, Inc, Boston, MA). A solid-phase ELISA was performed, based on the "dual antibody immunometric sandwich" principle. Two monoclonal antibodies (MoAbs) captured and bound the TNF-a. A third enzyme labeled goat antibody (conjugated with alkaline-phosphatase) was incubated in the wells. The bound specific anti-TNF antibody was quantitated by an enzymatic reaction.
Soluble ZL-2Ra The soluble IL-2Ra (Tac p 55) was measured by ELISA (Immunotech-France, SA, Marseille). This assay uses MoAbs directed against two different epitopes of the human IL-2Ra. In the wells of a microtiter plate coated with anti-rIL-2R MoAb, samples were incubated in the presence of a second MoAb conjugated with alkaline-phosphatase. After incubation, the wells are emptied by aspiration and rinsed. The amount of bound enzyme-conjugate was measured by adding a chromogenic substrate.
Blood samples were centrifuged, the serum decanted, and stored at -20°C until analysis.
TNF-a Evaluation of Response
Response was assessed according to the 1988 National Cancer Institute (NCI) sponsored workshop recommendations on AML.2'
RESULTS
Response to Therapy
Two patients achieved a complete remission after IL-2 therapy alone ( Peripheral blood counts of these two patients are displayed in Table 3 ; unique patient number (UPN) 4's platelet level did not reach 100,000/mm3, but it must be emphasized that this patient had undergone three BMT. According to NCI criterias," a third patient (UPN 3) had a significant response to rIL-2 therapy.
Toxicities Management
Treatment deliverance was modulated according to toxicities occurrence ( Table 4) . Nonhematologic side effects consisted in usual rIL-2-related toxicities (ie, hemodynamic and metabolic). In this special population, most of the individuals had poor hematopoietic functions before treatment, especially for platelets. This difficulty was overcome by systemic transfusions when platelet counts were under 30,000/mm3.
Immunologic Parameters
rIL-2 treatment was associated with lymphocytosis. No correlation was found between response and evolution of immunologic parameters (Table 5 ). Patient no. 1, who reached complete remission, had a dramatic increase in TNF-a levels. This was not documented for the second patient who had complete response (UPN 4).
DISCUSSION
In this report, we document the induction of two complete remissions and one partial remission in 10 AML treated in relapse by human rIL-2, the major T-cell growth factor. This clinical observation confirms previous in vitro data suggesting that leukemic populations could be controlled through immune a~tivation.'".'~ Our results are consistent with those initially reported by Rosenberg et al' in renal carcinomas and melanomas, and can be extended to other tumors including hematologic malignancies such as some non-Hodgkin's lymphomas, indicating that in vivo therapy with rIL-2 can induce the regression of a variety of established neoplasms.
The three patients with response had M5 FAB subtype. However, this is not enough to hypothesize a particular sensibility of this subgroup, the more so as contradictory data exists. 23 The first patient who reached complete remission, although being a true AML, had a pecular NK phenotype. This phenotype in favor of the immaturity of the leukemic clone24~25 may also promote the response to rIL-2 therapy. However, this is difficult to assess: indeed, the mechanisms of the antineoplasic action of IL-2 are complex and difficult to demonstrate. They involve the generation of effector cells like activated NK cells and T lymphocytes, as well as the induction by IL-2 of a cytokine "cascade" with secretion of other factors such as y-interferon and TNF. These can both have a direct effect on tumor and synergistic effects For personal use only. on September 14, 2017. by guest www.bloodjournal.org From tant in the control and the cure of AML came from data obtained after allogeneic BMT performed with a T-celldepleted graft. In this setting it was shown that depletion of T cells from the donor's marrow significantly increased the rate of relapse in various leukaemias, including AML."-*"
The fact that in vivo therapy with IL-2 could lead to the regression of relapsed AML suggests the clinical value of modern forms of immunotherapy using recombinant cytokines in this disease. This suggestion invites further clinical studies aimed at activating the immune system of patients in remission after chemotherapy or autologous BMT.30. 3' 28. Ostensen ME, Thiele DL, Lipsky PE: Tumor necrosis factor alpha enhances cytolytic activity of human natural killer cells. J Immunol138: 4185, 1987 29. Mannoni P, Lopez M, Maroc N, Fay C, Torres H, Razanajaona D, Tabilio A, Birg F Role of haematopoietic growth factors in the proliferation of acute myeloid leukemias, in Baum S (ed):
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